</s><s><s><s> human papillomavirus ( hpv ) 9-valent vaccine, recombinant, has been approved by the us food and drug administration and the u.s. centers for Disease control and prevention ( cdc ) for use in girls and boys in the united states and the united kingdom. 
 this vaccine is approved for use by the cdc, us department of health and human services, and the f ood and the us drug administration, respectively, and is licensed by the fdc for use with a 2-dose schedule in girls vs a 3-dose regimen in women. in this article 
, we review the literature on the use of this vaccine and review recommendations of the advisory committee on immunization practices. </s>